Why the study?
Do SK4 channel blockers reduce arrhythmic features in preclinical models of CPVT?
Do SK4 channel blockers reduce arrhythmic features in preclinical models of CPVT?
SK4 Ca2+-activated K+ channels play a critical role in adult pacemaker function and represent promising therapeutic targets for treating ventricular arrhythmias like CPVT.
Answers are grounded in this paper and cite their sources.
SK4 channels may offer a therapeutic target in CPVT; leaves open clinical translation from hiPSC models.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a stress‐provoked ventricular arrhythmia, which also manifests sinoatrial node (SAN) dysfunction. We recently showed that SK4 calcium‐activated potassium channels are important for automaticity of cardiomyocytes derived from human embryonic stem cells. Here SK4 channels were identified in human induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs) from healthy and CPVT2 patients bearing a mutation in calsequestrin 2 (CASQ2‐D307H) and in SAN cells from WT and CASQ2‐D307H knock‐in (KI) mice. TRAM‐34, a selective blocker of SK4 channels, prominently reduced delayed afterdepolarizations and arrhythmic Ca 2+ transients observed following application of the β‐adrenergic agonist isoproterenol in CPVT2‐derived hiPSC‐CMs and in SAN cells from KI mice. Strikingly, in vivo ECG recording showed that intraperitoneal injection of the SK4 channel blockers, TRAM‐34 or clotrimazole, greatly reduced the arrhythmic features of CASQ2‐D307H KI and CASQ2 knockout mice at rest and following exercise. This work demonstrates the critical role of SK4 Ca 2+ ‐activated K + channels in adult pacemaker function, making them promising therapeutic targets for the treatment of cardiac ventricular arrhythmias such as CPVT.
No takes yet. Share an insight, caveat, or question.
Haron‐Khun et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: